The pharma group did not break down the details of the license to get control of STX-478, described as a next-generation PI3K alpha inhibitor for breast cancer and other advanced solid tumours ...
Eli Lilly has agreed to acquire Scorpion Therapeutics’ breast cancer treatment program for up to $2.5 billion in cash. The drugmaker said Monday it is acquiring Scorpion and its STX-478 program ...
Stocktwits on MSN11d
Recursion Pharma Gets A Price-Target Cut After Q4 Miss: Retail Bearish Even As Cathie Wood's Ark Buys The DipShares of Nvidia-backed Recursion Pharmaceuticals Inc. (RXRX) ended Friday lower, extending weekly losses past 21% after ...
as signaled by the potential $2.5 billion deal signed recently to take over Scorpion Therapeutics Inc. and gain rights to phase I/II-stage STX-478 for breast cancer and other solid tumors.
Leerink lowered the firm’s price target on Recursion Pharmaceuticals (RXRX) to $6 from $7 and keeps a Market Perform rating on the shares after ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback